AOC3 and type 2 diabetes mellitus: Higher VAP-1 levels have also been demonstrated to be associated with an increased risk of MACE in diverse populations, including patients with heart failure (19), hemodialysis (20), T2DM (21), and individuals over 50 years of age who have not previously experienced (22).